Low-frequency ultrasound-mediated cytokine transfection enhances T cell recruitment at local and distant tumor sites
Tali Ilovitsh,Yi Feng,Josquin Foiret,Azadeh Kheirolomoom,Hua Zhang,Elizabeth S. Ingham,Asaf Ilovitsh,Spencer K. Tumbale,Brett Z. Fite,Bo Wu,Marina N. Raie,Nisi Zhang,Aris J. Kare,Michael Chavez,Lei S. Qi,Gadi Pelled,Dan Gazit,Ophir Vermesh,Idan Steinberg,Sanjiv S. Gambhir,Katherine W. Ferrara
DOI: https://doi.org/10.1073/pnas.1914906117
IF: 11.1
2020-05-19
Proceedings of the National Academy of Sciences
Abstract:Significance While immunotherapy has shown great promise for the treatment of T cell-inflamed tumors, a large fraction of cancer patients has not yet seen the benefit of immunotherapy. Furthermore, many immunotherapy protocols involving the systemic administration of multiple immunomodulatory antibodies create a significant toxicity. The platform technology under development here aims to address the need for local effective and nontoxic therapy by developing a minimally invasive tumor transfection method with minimal off-target toxicity. Local administration of a plasmid and microbubbles, coupled with image-guided low-intensity ultrasound, provides a safe and effective method to create a T cell-inflamed tumor. This technology was used to produce an anticancer cytokine and consequently recruit efficacious immune cells at both the local and distant tumor sites.